- The trend backdrop is active with a 10-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Activity pressure is positive on the latest completed week.
NN6
GER
Week ended 07 Aug 2026
Weekly Investor Report
NanoRepro AG · Healthcare · Diagnostics & Research
Latest close
1.98 EUR
3.9%
latest week
Weekly setup
Mixed setup
The weekly trend is active. Price is 17.2% above the Trend Line and sits at 61.0% of its 52-week range. The latest completed week returned 3.9%, after a -8.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
50
out of 100
Latest Close
1.98 EUR
7 Aug 2026
1W Return
3.9%
latest completed week
4W Return
-8.1%
short-term follow-through
12W Return
29.1%
quarterly tape
Trend Breadth
46.2%
24 of 52 weeks active
Volume Ratio
0.7x
vs 13-week average
- Next-week expectancy is negative at 42.52% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.9%
Latest completed week; four-week move -8.1%.
Indicator stack
60/63
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.52%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
2 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 17.2% above the Trend Line and sits at 61.0% of its 52-week range. The latest completed week returned 3.9%, after a -8.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.9212-week average 0.54
12-week confirmation
Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.92Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -8.1% over four weeks, 29.1% over 12 weeks, and 26.2% over one year. The current trend has remained active for 10 consecutive weeks.
Performance by holding period
Active trend streak10 weeks
Active weeks in one year24
Trend breadth46.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.93Latest activity-pressure read.
Pressure change-40.6%Four-week change in activity pressure.
Leadership9.30Latest relative-leadership reading.
RS change-66.0%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 30 Jun 2025
Field coverage 76%
Model confidence 39%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength54/100Blend of value, momentum, and quality. Underlying universe rank 47; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum51/100Medium-term price momentum. Underlying universe rank 50; rank 1 is best.
Growth51/100Revenue and earnings growth. Underlying universe rank 50; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 5.4x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- 53.7% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 63.4% Gross profit retained from each unit of revenue.
- Operating margin
- -74.2% Operating profit retained from revenue.
- Free-cash-flow margin
- 203.5% Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 43.2% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- 0.8% Net share repurchases relative to market value.
- Shareholder yield
- 0.8% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.1x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 2 relevant articles.
0 positive · 2 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-17.7%Distance below the 52-week high.
13-week volatility6.5%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher12 of 2613 weeks finished lower.
Best week+14.1%Week of 19 Jun.
Worst week-9.5%Week of 31 Jul.
Latest week+3.9%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains5
Flat weeks1
Modest losses10
Sharp losses3
Recent vol6.5%13-week weekly-return volatility.
Base vol5.0%52-week weekly-return volatility.
Up/down split23/28Count of positive and negative weeks in the 52-week window.
Average skew4.7% / -2.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorDE Healthcare
4-week rank72 / 78
Group average1.4%
Trend breadth39.7%
Trend39.7%active weekly trend signals
MD69.2%positive activity pressure
RS34.6%positive relative leadership
Four-week leaders
IndustryDE Diagnostics & Research
4-week rank6 / 6
Group average1.9%
Trend breadth33.3%
Trend33.3%active weekly trend signals
MD100.0%positive activity pressure
RS50.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape51/100
Trend, activity pressure, participation, and risk combine to a 51/100 tape read.
Indicator analysis86/100Latest 12-week confirmation: trend 10/12, activity pressure 12/12, relative leadership 12/12.
Activity pressure 0.92; No reversal markers Next-Week ExpectancyNegative 42.52%Next-week expectancy is negative with a 42.52% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors50/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 31 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment50/100Weighted news tone is neutral across 2 relevant articles.
NanoRepro AG (NN6.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1.98 EUR | 3.9% | 1.68 EUR | 1.74 EUR | 0.93 | 9.30 | 47.4K | On |
| 31 Jul 2026 | 1.90 EUR | -9.5% | 1.67 EUR | 1.74 EUR | 1.29 | 8.29 | 100.4K | On |
| 24 Jul 2026 | 2.10 EUR | -7.9% | 1.66 EUR | 1.74 EUR | 1.58 | 22.40 | 71.8K | On |
| 17 Jul 2026 | 2.28 EUR | 6.0% | 1.64 EUR | 1.74 EUR | 1.60 | 35.15 | 75.7K | On |
| 10 Jul 2026 | 2.15 EUR | -0.5% | 1.61 EUR | 1.74 EUR | 1.56 | 27.35 | 152.7K | On |
| 3 Jul 2026 | 2.16 EUR | 3.8% | 1.59 EUR | 1.74 EUR | 1.44 | 25.27 | 75.8K | On |
| 26 Jun 2026 | 2.08 EUR | 3.0% | 1.57 EUR | 1.74 EUR | 1.35 | 26.75 | 5.7K | On |
| 19 Jun 2026 | 2.02 EUR | 14.1% | 1.55 EUR | 1.74 EUR | 1.47 | 22.13 | 33.8K | On |
| 12 Jun 2026 | 1.77 EUR | -0.6% | 1.54 EUR | 1.74 EUR | 1.53 | 8.81 | 19.4K | On |
| 5 Jun 2026 | 1.78 EUR | -2.7% | 1.53 EUR | 1.74 EUR | 1.46 | 8.94 | 16.1K | On |
| 29 May 2026 | 1.83 EUR | 10.9% | 1.53 EUR | 1.75 EUR | 1.21 | 10.55 | 128.7K | Off |
| 22 May 2026 | 1.65 EUR | 7.8% | 1.52 EUR | 1.75 EUR | 1.00 | 0.96 | 83.9K | Off |
| 15 May 2026 | 1.53 EUR | 2.0% | 1.52 EUR | 1.75 EUR | 0.75 | -2.45 | 40.1K | Off |
| 8 May 2026 | 1.50 EUR | -1.0% | 1.53 EUR | 1.76 EUR | 0.49 | -5.60 | 12.7K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.